Certelli Camilla, Russo Silvio Andrea, Palmieri Luca, Foresta Aniello, Pedone Anchora Luigi, Vargiu Virginia, Santullo Francesco, Fagotti Anna, Scambia Giovanni, Gallotta Valerio
Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Cancers (Basel). 2023 Sep 28;15(19):4769. doi: 10.3390/cancers15194769.
The role of secondary cytoreductive surgery (SCS) in the treatment of recurrent ovarian cancer (ROC) has been widely increased in recent years, especially in trying to improve the quality of life of these patients by utilising a minimally-invasive (MI) approach. However, surgery in previously-treated patients may be challenging, and patient selection and surgical planning are crucial. Unfortunately, at the moment, validated criteria to select patients for MI-SCS are not reported, and no predictors of its feasibility are currently available, probably due to the vast heterogeneity of recurrence patterns. The aim of this narrative review is to describe the role of secondary cytoreductive surgery and, in particular, minimally-invasive procedures, in ROC, analyzing patient selection, outcomes, criticisms, and future perspectives.
近年来，二次减瘤手术（SCS）在复发性卵巢癌（ROC）治疗中的作用已得到广泛提升，尤其是在尝试通过采用微创（MI）方法来改善这些患者的生活质量方面。然而，对先前接受过治疗的患者进行手术可能具有挑战性，患者选择和手术规划至关重要。不幸的是，目前尚未报道用于选择MI-SCS患者的有效标准，而且目前也没有其可行性的预测指标，这可能是由于复发模式存在巨大异质性所致。本叙述性综述的目的是描述二次减瘤手术，特别是微创操作在ROC中的作用，分析患者选择、结果、批评意见及未来展望。
